CSCGlobal reduces stake in Cohance Lifesciences through promoter share sale

CSCGlobal Capital Markets (Singapore) Pte. Ltd. has disclosed, under SEBI regulations, the release of encumbrance on shares in Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited). This follows an on-market sale of 3,41,48,000 equity shares by Jusmiral Holdings Limited, a Cohance promoter. The transaction, executed on September 18, 2025, represents an 8.93% stake (8.84% on a fully diluted basis).

Prior to this sale, Jusmiral Holdings Limited held 12,65,38,578 encumbered shares, accounting for 33.08% of the total equity (32.75% diluted). Following the sale, Jusmiral's encumbered shareholding decreased to 9,23,90,578 shares, representing 24.15% of the total equity (23.91% diluted).

These shares were subject to restrictions under a Notes Purchase Agreement dated May 29, 2024. In this agreement, CSCGlobal Capital Markets (Singapore) Pte. Ltd. acts as agent and security agent for the Finance Parties. The agreement included covenants preventing Jusmiral Parent, a wholly-owned subsidiary of Jusmiral Holdings Limited, from disposing of or creating security on its holdings in Jusmiral Holdings Limited, except as permitted.